Skip to main content
Industry News
Epizyme's Tazverik gains conditional approval for rare soft tissue sarcoma

The FDA granted conditional approval to Epizyme's Tazverik, or tazemetostat, to treat patients with inoperable metastatic or locally advanced epithelioid sarcoma, a rare soft tissue cancer, and Epizyme announced the drug will be priced at $15,500 per month. Data from a midstage trial showed the drug shrank tumors in some patients.

Full Story: